Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

In the summer of 2024, Karsten Heuer and his wife Leanne Allison hiked to a remote area of Banff National Park.

A Florida man with a terminal illness faces losing vital hospice care due to an administrative error, leaving his family in ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of earnings.

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

Theravance Biopharma (TBPH) stock is in focus as the firm halts the clinical program for rare disease therapy ampreloxetine following a trial setback. Read more here.

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

At the conference, Dr. Stamler will participate in a fireside chat entitled, “Optimising Late-stage Clinical Trials to Increase the Odds,” and will also host 1-on-1 investor meetings.

By Padmanabhan Ananthan March 3 (Reuters) - Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a possible sale, after scrapping development of an ...